Amlexanox vs Semaglutide
A side-by-side research comparison of Amlexanox and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Amlexanox | Semaglutide |
|---|---|---|
| Full name | Amlexanox (TBK1/IKKε Inhibitor) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research / Off-label | FDA Approved |
| Mechanism | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 298.29 Da | 4,114 Da |
| Half-life | ~3-4 hours | 7 days (168 hours) |
| Bioavailability | ~70% oral | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 25-100 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 3x daily | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.